Engaging the Patient with AF in Optimizing Care

  
Jointly sponsored by North American Center for Continuing Medical Education, LLC and Horizon CME

Cardiovascular Learning Network, A NACCME Initiative

Presenters

Peter J. Kudenchuk, MD, FACP, FACC, FAHA
Professor of Medicine
University of Washington
Associate Medical Director
Seattle/King County Emergency Medical Services
Seattle, Washington

Bruce Stambler, MD
Clinical Electrophysiology and Pacing
University Hospitals Case Medical Center
Professor, Case Western Reserve University
Cleveland, Ohio

Intended Learners

This activity is designed for cardiologists, nurses, and nurse practitioners who treat patients with atrial fibrillation (AF).

Learning Objectives

After completing this activity, participants should be able to:

• Summarize current clinical trial data on ablation, rate- and rhythm-control, and their impact on cardiovascular outcomes
• Incorporate new guidelines for antiarrhythmic drug (AAD) treatment in specific AF patients with different comorbidities and clinical presentations
• Implement strategies for safe and effective switching of AADs
• Engage patients in meaningful communication to improve adherence to guideline-recommended AF therapy
• Apply guideline recommended anticoagulants and validated stroke risk scoring systems in clinical practice for the management of patients with AF

Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Release Date: December 20, 2011
Expiration Date: December 20, 2012
Estimate time to complete: 1.5 hours

There is no fee associated with this activity.

For questions regarding this activity, please call 609-371-1137.

Accreditation

This activity has been planned and implemented by North American Center for Continuing Medical Education, LLC and Horizon CME for the advancement of patient care. North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards 1.5 contact hours

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.5 contact hours.

AANP Accreditation

This program is approved for 1.5 contact hour of continuing education by the American Academy of Nurse Practitioners. Program ID 1112381

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Independent Clinical Reviewer: Marco Mercader, MD, Associate Professor, Cardiac Electrophysiology, George Washington University

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Planning Committee

The planning committee comprises Michael D. Ezekowitz, MBChB, DPhil, FRCP, FAHA, FACC, Julia H. Indik, MD, PhD, Peter J. Kudenchuk, MD, FACP, FACC, FAHA, Marco Mercader, MD, Alan B. Miller, MD, Peter Ott, MD, FACC, Susie Seaman, NP, Bruce Stambler, MD, and Eric C. Stecker, MD, MPH; Laura D’Onofrio, Mary Johnson, Mike Kearney, Randy Robbin, John Savage, and Jessica Steuerman, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Ezekowitz: Consultant—Boehringer-Ingelheim, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Johnson & Johnson, Medtronic, Pfizer, Portola, sanofi-aventis U.S.
Dr. Kudenchuk: Grant/Research support—NIH/NHLBI; Promotional speakers bureau—Boehringer-Ingelheim, sanofi-aventis U.S.; Stock shareholder—sanofi-aventis U.S.
Dr. Mercader: Grant/Research support—Cheney Cardiovascular Institute Grant, Medical Faculty Associates and George Washington University-Collaborative Research Grant
Dr. Miller: Grant/Research support—Cardioxyb; Consultant—Biocontrol, Biotronik, Columbia University, Medtronic, Merck, St. Jude Medical; Promotional speakers bureau—Boehringer-Ingelheim, Gilead, Otsuka, sanofi-aventis U.S.; Employee—University of Florida
Dr. Ott: Promotional speakers bureau—Boston Scientific, Medtronic, St. Jude Medical
Ms. Seaman: Scientific advisor—Mölnlycke Health Care; Promotional speakers bureau—Mölnlycke
Dr. Stambler: Grant/Research support—Pfizer; Consultant— Johnson & Johnson, sanofi-aventis U.S.; Promotional speakers bureau—Boehringer-Ingelheim, sanofi-aventis U.S.
Dr. Stecker: Grant/Research support—Biotronik, Boston Scientific, Medtronic
Dr. Indik disclosed no relevant financial relationships with any commercial interests.

Ms. D’Onofrio, Ms. Johnson, Mr. Kearney, Mr. Robbin, Mr. Savage, and Ms. Steuerman disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that the following off-label/unapproved uses and/or devices will be discussed: The investigational use of amiodorone, apixaban, betrixaban, and endoxaban in the treatment of AF.

Hardware/Software Requirements:

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2011 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support

Supported by an independent educational grant from sanofi-aventis U.S.